You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Type 2 Issues Articles
Popular Type 2 Issues Articles
Highly Recommended Type 2 Issues Articles
Send a link to this page to your friends and colleagues.
A Canadian clinical study has delivered a double dose of good news for proponents of exenatide (sold commercially as Byetta), a drug used by more than 700,000 Americans to control blood glucose, ease food cravings, and, incidentally, lose weight.
An experimental long-term version, injected once weekly (versus the twice-daily routine in current use), provides better control of blood sugar and is better tolerated by users' gastrointestinal systems.
Those are the conclusions of a study by Dr. Daniel Drucker and colleagues at the Mount Sinai Hospital and University of Toronto in Ontario, Canada. Dr. Drucker's study was presented at a recent meeting of the European Association for the Study of Diabetes in Rome, and will be published in the British medical journal The Lancet.
The randomized trial followed 259 type 2 diabetes patients who had had diabetes an average of nearly seven years, tracking their A1c levels for 30 weeks. The mean A1c level for the group was 8.3% at the start of the study.
One group of 129 patients received a once-weekly 2 mg (milligram) injection of exenatide. The other group of 130 patients received exenatide injections of 10µg (micrograms) twice daily.
The patients on the once-weekly regimen saw their A1c levels fall to a mean of 6.4% (a -1.9% improvement), while those taking the drug twice daily saw their A1c's fall to 6.8% (a -1.5% improvement).
More patients in the once-weekly group, 77 percent, achieved the study target of an A1c of 7.0% or less, compared with 61 percent of those in the twice-daily group.
The percentages of those achieving A1c's of 6.5% or less were similar in both groups. The authors concluded, "Exenatide once weekly resulted in significantly greater improvements in glycemic control than exenatide given twice a day, with no increased risk of hypoglycemia and similar reductions in bodyweight."
The study is available online.
3 comments - Sep 11, 2008
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.